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Background: Behçet’s disease (BD) is a systemic vasculitis with unknown aetiology, where, besides genetic
predisposition, an immune dysregulation involving T and B lymphocytes and hyperactive neutrophils contribute to
disease pathogenesis. The aim of this study was to determine the cytotoxicity of natural killer (NK) cells in
bronchoalveolar lavage (BAL) from BD patients with pulmonary manifestations.
Methods: BAL was performed in 27 patients with BD and pulmonary manifestations, 14 patients with Rheumatoid
Arthritis (RA) and 23 healthy controls (HC). Related orphan receptor C (RORC) and forkheadbox P3 (FOXP3) mRNA
transcript were determined in BAL by reverse transcription–polymerase chain reaction (RT-PCR). NK cells, NK cell
cytotoxicity, and lymphokine-activated killer (LAK) activity against K562 cells were measured by flow cytometry.
Proportions of NK precursors and expression of genes for IL-2 receptor β (IL-2Rβ; CD122), perforin, and granzyme in
NK cells were measured by flow cytometry or RT-PCR.
Results: The analysis of transcription factors revealed an increase in the RORC/FOXP3 ratio (Th17/Treg cells) in BAL
from BD patients. Percentages of NK were significantly lower in BD than in RA patients and healthy controls.
Purified NK cells derived from BD patients were found to have lower cytotoxicity and LAK activity than those from
controls. This defect of NK cells in BD patients was related to down-regulation of perforin and granzyme expression
in NK cells.
Conclusion: In BD patients, the increased RORC/FOXP3 ratio indicated an inflammatory state of the lung. NK cells
were decreased together with an impairment of their activity due to a defective expression of granzyme and
perforin. These abnormalities possibly contribute to immune system dysregulation found in BAL of BD patients with
pulmonary manifestations.
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Behçet’s disease (BD) is a systemic vasculitis with un-
known aetiology. Immune dysregulation involving T and
B cells with hyperactive neutrophils, supposedly triggered
by infectious agents, contribute to disease pathogenesis
in addition to genetic predisposition [1]. Documentation
of various atypical streptococcal species in oral flora of
BD patients, clinical flares after dental procedures and a
good response to antibacterial treatment have been con-
sidered as evidence for the role of Streptococcus in BD
[2]. However, none of the microbial agents has been* Correspondence: kamel.hamzaoui@gmail.com
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reproduction in any medium, provided the ordefinitely proved to cause BD. Immunological disorders
are important in BD pathogenesis [3]. T lymphocytes
from patients with BD produced a particular pattern of
inflammatory mediators when stimulated with a bacterial
superantigen, and innate immunity was deeply investi-
gated in BD patients [4].
In Behçet’s disease, vascular system involvement is the
main cause of mortality. Pulmonary artery aneurysms,
arterial and venous thrombosis, pulmonary infarction,
recurrent pneumonia, bronchiolitis obliterans organized
pneumonia, and pleurisy are the main features of pul-
monary involvement in BD [5,6]. Inflammatory features
characterize bronchoaveolar lavage (BAL) from BD pa-
tients with pulmonary involvement. B cell-activating fac-
tor of the TNF family (BAFF), an important regulator ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bination is increased in BD lung and contributes to im-
munoglobulin synthesis [7]. Both interleukin 18 (IL-18)
and gamma interferon (IFN-γ), contribute to the local
inflammatory response in BAL from BD patients [8]. Re-
cently Toll-like receptors expressing cells and NOD-like
receptors (NLRs) were found to synergize for the induc-
tion of proinflammatory cytokines in BAL from BD pa-
tients with pulmonary manifestations [9].
As major components of innate immunity, Natural killer
(NK) cells not only exert cell-mediated cytotoxicity against
tumour or infected cells, but also regulate other immune
cells functions by secretion of cytokines and chemokines.
Due to these effector functions, NK cells play a significant
role in host defense against malignancies and certain vi-
ruses and they may also be important in the regulation of
autoimmunity [10]. However, the effector function of NK
cells must be exquisitely controlled in order to prevent in-
advertent attack against self normal cells. Patients with ac-
tive BD show impaired NK cytotoxicity [11-14]. Impaired
NK cytotoxicity in first-degree relatives of BD patients was
recently reported [14-16], which suggests that NK cell defi-
ciency, may be a genetic determinant of BD.
The aim of the present study was to determine the ex-
pression of retinoid-related orphan receptor C (RORC)
(Th17), forkheadbox P3 (FOXP3) (Treg) and the cytotox-
icity of pulmonary NK cells in BD. We determined NK cell
levels, NK cytotoxicity, and lymphokine-activated killer
(LAK) activity in BAL of patients with BD. Proportions of
NK precursors and expression of genes for IL-2 receptor
β-chain (IL-2Rβ; CD122), perforin, and granzyme in
NK cells were measured by flow cytometry or reverse
transcription–polymerase chain reaction (RT-PCR).
Methods
Patients
The study group consisted of 27 BD patients (19 males,
8 females, age 34 ± 10 years; range 17–56 years) all ful-
filling the international study group criteria for Behcet’s
disease [17], with a disease duration ranging from 1 to
9 years (mean ± SD: 5.8 ± 3.4). Twenty three BD pa-
tients were never-smokers and 4 ex-smokers. All pa-
tients had active BD with pulmonary manifestations
[8,9] including eye lesions (14 patients: 51.85%), oral ul-
cers (27 patients: 100%) , genital ulcers (18 patients:
66.67%), arthritis (16 patients: 59.25%), and vascular
symptoms (12 patients: 44.45%). Pulmonary vascular
abnormalities were as follows: asymptomatic functional
abnormalities (8 patients), pulmonary artery aneurysm
(6 patients), pulmonary artery embolism (9 patients), and
pulmonary venous abnormalities (4 patients). They were
treated with steroids and colchicine. Remission was de-
fined when clinical manifestations were lost (eye lesions,
oral and genital ulcers, and arthritis). Asymptomaticfunctional abnormalities diminished after corticosteroid
treatment. Rheumatoid arthritis patients (RA: 10 men
and 4 women; mean age: 46.2 ± 9.5 years; range: 42–50
years) acted as control disease. The control subjects
consisted of 23 non-smokers (18 men and 5 women;
mean age: 42.8 ± 7 years; range: 38–52 years) undergoing
routine investigations for suspected bronchial carcinoma
and whose chest X-ray, bronchial examination, and pul-
monary function were normal. None of them had evi-
dence of acute infection or chronic disease (e.g., other
autoimmune or atopic disorders). Our hospital ethic
committee approved the design of the study and BAL
was obtained after informed consent.
Monoclonal antibodies (mAb) and flow cytometry
The following mAb and reagents were used in this
study: fluorescein isothiocyanate (FITC)–conjugated
or peridinin chlorophyll A protein–conjugated anti-
CD3 mAb, FITC-conjugated anti-CD45 mAb, FITC-
conjugated or phycoerythrin (PE)–conjugated anti-CD56
mAb, PE-conjugated anti-CD16 mAb, PE-conjugated
anti-CD122 mAb, and FITC-conjugated antiperforinmAb
(all from Becton Dickinson, San Diego, CA). Cells were
stained with combinations of appropriate mAb at 4°C for
20 minutes. Stained cells were analyzed on a FACsCalibur
flow cytometer using Cell Quest software (BD Biosciences,
Mountain View, CA).
Bronchoalveolar lavage
BAL was obtained as we previously reported [9]. Briefly,
bronchoscopy was performed according to standard
guidelines [18]. Thirty minutes prior to the procedure
patients received 0.5 mg of atropine and 12.5 mg co-
deine intramuscularly. Local anaesthesia of the orophar-
ynx was achieved by xylocaine instillation until gag
reflexes subsided. Bronchoscopy was performed using a
Pentax bronchoscope through which 150 ml of normal
prewarmed saline in aliquots of 50 ml were instilled into
a subsegment of the right middle lobe. BAL fluid (BALF)
was then immediately aspirated by gentle hand suction
into plastic tubes and kept at 4°C on ice.
BALF was concentrated 10 fold before analysis whilst a
great part of the cell pellets were immediately fixed in
RNA stabilisation buffer. The total count of nucleated cells
was performed as we have recently reported [9]. Differen-
tial cell count was determined by cytological examination
of at least 500 cells after centrifugation in a cytospin
(Shandon) and May-Grünwald-Giemsa staining. Cell per-
centages were recorded for every patient. The rest of BALF
was centrifuged at 400 g for 10 min and the pellet was
processed for lymphocyte subset of (Th17) and regulatory
T cells (Treg) determination. All BALF were analyzed at
the time of processing and only technically appropriate
BALF were retrospectively reviewed.
Hamzaoui et al. Multidisciplinary Respiratory Medicine 2013, 8:29 Page 3 of 8
http://www.mrmjournal.com/content/8/1/29Flow cytometric assays of the cytotoxicities of BAL cells
and purified NK cells
BAL cells and BAL-isolated NK cells were used as effector
cells and were cultured for 4 hours at 37°C in complete
media, consisting of RPMI 1640, 2 mM-glutamine,
100 units/ml of penicillin, 100 μg/ml of streptomycin,
and supplemented with 10% fetal bovine serum (FBS;
Gibco BRL, Grand Island, NY) in a humidified incuba-
tor containing 5% CO2. K562 cells (CCL-243; American
Type Culture Collection, Manassas, VA) were used as
target cells. Effector and target cells were mixed in 12 ×
75–mm round-bottomed polystyrene tubes (Becton
Dickinson) at different effector-to-target (E:T) cell ra-
tios. Control tubes including only target cells were also
assayed to quantify spontaneous K562 cell death. Tubes
were incubated for 4 hours at 37°C in a humidified in-
cubator containing 5% CO2.
To determine LAK activities, 200 IU/ml of recombin-
ant IL-2 (BD PharMingen, San Jose, CA) was added to
the tubes. Mixed effector and target cells were stained
with FITC-conjugated anti-CD45 mAb at 4°C for 20 mi-
nutes, washed once in phosphate buffered saline (PBS),
resuspended in 0.5 ml of PBS containing 20 μl of 1 μg/ml
propidium iodide (BD PharMingen), and incubated at
room temperature for 15 minutes. Percentages of dead
K562 cells were determined by flow cytometry. Cytotox-
icities were calculated by subtracting the percentages of
dead K562 cells in control tubes from the percentages of
dead cells in sample tubes.
RT-PCR
Total cellular RNA was extracted from isolated BAL
cells and NK cells using RNAzol B (Tel-Test, Friends-
wood, TX), according to the manufacturer’s instruc-
tions. Aliquots (3 μg) of total cellular RNA were
transcribed into complementary DNA (cDNA) at 37°C
for 1 hour in a total volume of 20 μl using 2.5 units of
Moloney murine leukemia virus reverse transcriptase
(Roche, Germany). Reverse-transcribed cDNA samples
were then added to a PCR mixture consisting of 10×
PCR buffer, 0.2 mMdNTPs, 0.5 units of Taq DNA poly-
merase (Biocare Lab, Tunisia), and 10 pmoles of
primers for each gene. The sequences of the primers
we used were as follows: for β-actin, 50-CTCCTTA
ATGTCACGCACGAT-30 (sense) and 50-GTGGGGCG
CCCCAG GCACCA-30 (antisense); for perforin, 50-
CTGCCGTGGATGCCTATG-30 (sense) and 50-CGGC
TCACACTCACAGG-30 (antisense); for granzyme, 50-
TACACACAAGA GCTCCAGAGT-30 (sense) and 50-
GGGGAAGCTCCATAAATGTCACCT-30 (antisense);
for CD122, 50-GGTCACCTGATAGTGGAGAA-30 (sense)
and 50-ACCTGAATCCAATTTCACAG-30 (antisense); for
c-Kit, 50-TTCTTACCAGGTGG CAAAGGGCATGGCT
TTCC-30 (sense) and 50-GTCATACATTTCAGCAGGTGCGTG TTCAGGGC-30 (antisense); and for Flt-3, 50-
GAGGACTTGAATGTGCTTACA-30 (sense) and 50-TCC
CACAGTAATATTCCATATGA-30 (antisense).
Amplifications were conducted over 28 cycles of 94°C
for 1 minute (denaturation), 55°C for 1 minute (annealing),
and 72°C for 1 minute (extension). This was followed by
an additional extension step at 72°C for 10 minutes in a
PCR cycler (Bio-Rad, CA). PCR products were subjected to
electrophoresis and visualized by ethidium bromide stain-
ing. Densities were analyzed versus β-actin by densitometry
using Alpha Ease FC image analysis software (Alpha
Innotech, CA). Results are presented as relative gene ex-
pression intensities.
Quantification of RORC/FOXP3 (Th17/Treg) ratios
The expression of mRNA for FOXP3 (Treg) and RORC
(Th17) was quantified using the Applied Biosystems
7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA) as we have recently reported
[9,12]. Amplification of cDNA was performed with the
TaqMan Universal PCR Master Mix (2×), No AmpErase
UNG (Applied Biosystems). A reaction volume of 25 μl
(1.0 μlcDNA) was amplified for 40 cycles of 10s at 95°C
and 1 min at 60°C. All samples were analyzed in dupli-
cate, and transcription expression was calculated as a
mean and standard deviation (SD). For quantification of
cDNA a five-point serially four-fold diluted standard
curve was developed from BAL cell cultures stimulated
with phytohaemagglutinin (PHA). The mRNA expres-
sion of the T cell transcription factors was standardized
to 18S (human rRNA) and all results are expressed as a
ratio. A coefficient of variance < 15% was accepted as
maximum variation among duplicates. The intra-assay
variance for 18S was 4.9%, FOXP3 6.1%, RORC 6.2%.
Samples revealing an undetectable expression in both
duplicates in three subsequent analyses were assigned an
expression quantity of zero. Primers and probes for
FOXP3 forward GTGGCCCG GATGTG AGAA, reverse
GCTGCTCCAG AGACTGTACCATCT, probe CCTCAA
GCACTGCCAGGCGGAC; 18S forward CGGCTACCA
CATCCA AGGAA, reverse GCTGGAATTACCGCGGCT,
probe GAGGGCAAGTCTGGTGCCA GCA. HPLC-
purified oligonucleotide primers and probes were
bought from MedProbe (Oslo, Norway). All in-house
designed mRNA amplicons included at least one exon–
exon boundary to assure specificity (marked in bold in
the sequences above), and reaction concentration was
optimized prior to analysis of samples.
Statistical analysis
The percentages of NK cells were log-transformed for
purposes of analysis. All comparisons of percentages of
NK cells and of cytotoxicity were made by analysis of
covariance after adjusting for age and sex using the
Figure 1 Transcription factor ratios in BAL cells. Values were
expressed as mean ± SD in the text. P is indicated in the Figure.
Data are shown as box plots. Each box represents the 25th to 75th
percentiles. Lines inside the boxes represent the mean. Whiskers
represent the 10th and the 90th percentiles.
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sons of CD3–CD122+ cell percentages and of CD122 sur-
face expression rates among NK cells were made by
analysis of variance with the Bonferroni correction for
multiple comparisons. P less than 0.05 was considered sta-
tistically significant. All statistical analyses were performed
using SPSS version 14.0 software (SPSS, Chicago, IL).
Results
Cell analyses and Th17/Treg ratio in bronchoalveolar
lavage
BAL fluids recovered from BD patients were more cellu-
lar than those from healthy controls and RA patients ,
containing significantly greater number of lymphocytes
(P< 0.05) [Table 1]. Expression of retinoid-related or-
phan receptor C (RORC) (Th17) and forkhead box P3
(FOXP3) (Treg) mRNA transcript were studied in BAL
cells from 27 BD patients with pulmonary manifesta-
tions, 14 RA patients and 23 healthy controls. FOXP3
was expressed at similar levels between BD patients
[1.62 ± 0.60%], RA patients [1.58 ± 0.44%] and healthy
controls [1.67 ± 0.59%; P = 0.85 and P = 0.77]. In con-
trast, RORC was highly expressed in BAL of BD patients
[1.93 ± 0.69%] compared to that of RA patients [0.76 ±
0.22%; P = 0.0001] and of healthy controls [0.85 ±
0.38%; P = 0.0001]. Th17/Treg (RORC/FOXP3) ratio
was increased in BD patients contrasting with values ob-
served in RA patients and in healthy controls (Figure 1).
Reduced numbers of circulating NK cells in BAL cells from
BD patients
The percentages of NK cells in the BAL of BD patients,
RA patients and healthy controls were determined by
flow cytometry. NK cell percentages were significantly
lower in BD patients [5.59% ± 2.22%], than in healthy
controls [12.60% ± 2.36%; P = 0.0001]. NK cells in RA
patients [10.50% ± 2.69%] were expressed at higher level
than in BD patients [P = 0.0001]. Low and significant
difference was found between RA and healthy controls
[P = 0.017] (Figure 2).
Impaired cytotoxicity of BAL NK cells in BD patients
To examine the cytotoxic effects of NK cells on K562 cells,
BAL from 27 BD patients, 14 RA patients, and 23 healthy
controls were used. The cytotoxicities of BAL cells wereTable 1 Differential cell count
Diseases Macrophages Lymphocytes Neutrophils Eosinophils
BD (n = 27) 72.5 ± 7.4 19.7 ± 4.3† 7.6 ± 10.9 1.9 ± 4.3
RA (n = 14) 72.6 ± 5,8 14.8 ± 9.7 10.3 ± 11.9 2.4 ± 3.6
HC (n = 23) 78 ± 6.8 12.5 ± 3.4 3.5 ± 1.4 0.5 ± 0.7
BD, Behçet’s disease; HC, Healthy control, RA, rheumatoidarthritis. Values are
presented as mean) ± SD. (†): Significance Behçet’s disease versus control
subjects and RA patients (P = 0.001).evaluated by flow cytometry and determined at an effector/
target (E:T) cell ratio of 10:1, 5:1 and 2.5:1. The cytotoxi-
cities were significantly lower in BD compared to NK acti-
vity in RA patients and in healthy controls (Figure 3A).
Several groups of investigators suggested that NK
cytotoxicity was enhanced by IL-2 [19]. LAK activity in-
duced by IL-2 was significantly lower in BD and RAFigure 2 Reduced numbers of NK cells in BAL of Behçet’s disease.
Freshly isolated bronchoalveolar cells from healthy controls, Rheumatoid
arthritis patients and BD patients were stained with fluorescein
isothiocyanate–conjugated anti-CD3 and phycoerythrin-conjugated
anti-CD56 monoclonal antibodies and then analyzed by flow cytometry.
Data are shown as box plots. Each box represents the 25th to 75th
percentiles. Lines inside the boxes represent the mean. Whiskers
represent the 10th and the 90th percentiles.
Figure 3 Decreased cytotoxicity of bronchoalveolar lavage cells from Behçet’s disease patients. Freshly isolated BAL cells were stained
with fluorescein isothiocyanate–conjugated anti-CD45 monoclonal antibody and then cocultured with K562 cells kine for 4 hours. Cytotoxicity
was determined as described in patients and methods and is expressed as the percentage of apoptotic K562 cells. For measurement of
lymphokine-activated killer (LAK) activity, interleukin-2 (IL-2; 200 IU/ml) was added to cocultures. Cytotoxicity [A] and LAK activity [B] were
determined in BAL cells from 23 healthy controls (HC), 14 patients with RA and 27 patients with Behçet’s disease (BD). Data are Mean ± SD.
Cytotoxicity was determined at an effector-to-target (E:T) cell ratio of 10:1, 5:1 and 2.5: 1.
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ities of BAL cells were significantly correlated with NK
cell percentages [NK activity: r = 0.590; P = 0.0012].
These findings suggest that impaired cytotoxicity of BAL
cells is caused by an NK cell deficiency. Cytotoxicities in
BAL from healthy controls were greater at higher E:T
cell ratios. This was also the case in BAL from BD and
RA patients.
Intrinsic defects of NK cells in BD patients
To examine whether defective killing by NK cells con-
tributes to the impaired cytotoxicity observed in BD pa-
tients, we compared the cytotoxicities of purified NK
cells obtained from the BAL of 10 BD patients, 7 RA pa-
tients and 10 BAL from healthy controls. The cytotoxic-
ities of purified NK cells were determined at an E:T cell
ratio of 10/1, 5:1 and 2.5:1. We found that cytotoxicities
and LAK activities were significantly lower in BD pa-
tients than in healthy controls. These values were signifi-
cantly lower in RA patients than in healthy controls
(Figures 4A and B). Cytotoxicities and LAK activities in-
creased in healthy controls and RA patients when E:T
cell ratios increased, which contrasted in BD patients.
These results suggest that killing deficits of NK cells
contribute to impaired cytotoxicity and LAK activity in
BAL from BD patients.
The expression of IL-2 receptor β-chain (IL-2Rβ,
CD122) is important for the differentiation of NK
cells. CD122 is regarded as a marker for NK precur-
sors. CD3+CD122+ cells include immature and mature
NK cells as reported by Huntington et al. [20]. We in-
vestigated the proportions of CD3+CD122+ cells in
BAL cells and IL-2Rβ-expressing cells in NK cells.The percentages of CD3+CD122+ cells and of CD122
expression on NK cells were significantly lower in BD
patients [CD3+CD122+: 5.32 ± 1.92%, P = 0.0001;
CD122-NK cells: 60.70 ± 13.70, P = 0.0001] than in RA pa-
tients [CD3+CD122+: 18.50 ± 3.27%; CD122-NK cells:
92.83 ± 10.11%] and in healthy controls [CD3+CD122+:
15.10 ± 3.70%; CD122-NK cells: 84.80 ± 7.68%;]. No dif-
ferences were observed between RA patients and healthy
controls [CD3+CD122+: P = 0.085; P = 0.093] (Figures 5A
and B). We also examined the expression levels of
CD122 and of the toxicity-related molecules perforin and
granzyme in BAL cells and purified NK cells. Gene tran-
scripts of CD122, perforin, and granzyme were found to
be markedly lower in BAL cells and NK cells from BD
patients (Figure 5C). Intracellular perforin expression in
NK cells was also lower in BD patients than in RA pa-
tients and in healthy controls (Figure 5D).
Discussion
The results of this study demonstrated that BAL cells
from BD patients display an inflammatory profile associ-
ated with an impairment of NK activity.
The number of Treg cells (FOXP3) was unaltered in
BD patients compared to controls, contrasting with an
increase in Th17 (RORC) subpopulation. These results
suggest that an imbalance of Th17/Treg in BAL cells
may be implicated in the pathogenesis of lung involve-
ment in BD. Increased expression of IL-17 in inflam-
matory sites supports a Th17-mediated inflammatory
pathway in several diseases [21-24].
In the present study, we found that NK cell number
and cytotoxicity were decreased in BAL from BD patients
with pulmonary involvement compared to RA patients
Figure 4 Decreased cytotoxicity of purified natural killer cells from Behçet’s disease patients. NK cells were isolated from BAL cells by
magnetic-activated cell sorting. Cytotoxicity and lymphokine-activated killer activity were determined as described in Figure 3. Cytotoxicity [A] and
LAK activity [B] of purified NK cells were determined in 5 healthy controls, 3 patients with RA and 7 patients with Behçet’s Disease. Data are shown
as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the mean. Whiskers represent the 10th and the 90th
percentiles. Cytotoxicity was determined at an effector-to-target (E:T) cell ratio of 10:1, 5:1 and 2.5:1.
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population of effector cytotoxic lymphocytes and a major
source of pro-inflammatory cytokines. CD3+CD122+ cell,
which include immature and mature NK cells [20], were
reduced in BAL from BD patients. Cytotoxicity of BAL
purified NK cells were markedly suppressed in BD pa-
tients. This activity was not diminished in RA patients.
Reduction of cytotoxicity in BD patients resulted from a
lowered NK cell number associated with an intrinsic NK
cell defect of granzyme expression. This is demonstrated
by down-regulation of IL-2Rβ, perforin, and granzyme in
NK cells in our patients.
NK cell numbers and activities were persistently low.
These data contrast with reported results on peripheral
circulation in BD patients, showing increased NK popu-
lation and high NK activity [11]. This could raise the
question of whether local reductions in NK cell number
and activity are a consequence of a defective differenti-
ation of hematopoietic stem cells into NK cells, as re-
cently described by Park et al. in systemic lupus patients
[11]. This point has to be investigated in a future report.
Intensity and quality of the NK cell cytotoxic response
depend on the cytokine microenvironment as well as on
immune system interactions [25,26]. These interactions in-
clude crosstalk between NK cells and dendritic cells (DCs)
or T lymphocytes, occurring initially in secondary com-
partments such as lymph nodes [27]. The phenotyping and
functional results from the present study are partially con-
sistent with these findings.
The reduced cytotoxicity in BAL from BD was merely
due to low perforin expression. Resting CD56dim NK
cells, which account for the majority of circulating NK
cells, express intermediate-affinity IL-2Rβ, mediates theinduction of LAK activity [28]. In mature NK cells,
IL-2Rβ is shared by IL-2 and IL-15, and IL-15 can effi-
ciently induce NK cell proliferation, differentiation, and ac-
tivation, which markedly increases NK cytotoxicity.
However, adjunction of IL-2 to BD NK cells yielded a re-
duced increase of cytotoxicity compared to controls. This
lowered effect of IL-2 on LAK activity in BD is associated
with a decrease in IL-2Rβ expression. As IL-2Rβ is critical
for LAK activity and NK cell differentiation, down regula-
tion of IL-2Rβ in NK cells from BD patients is consistent
with the reduced response of NK cells to IL-2.
A possible explanation is that NK cell depletion in
the BD lung patients occurs secondary to disease pro-
gression and to the localized important inflammation
existing in the lung. However, our present findings sug-
gest that numerical deficiencies and functional defects
of NK cells might play an active role in the pathogenesis
of BD, rather than being a consequence of the disease
process. Indeed, it has been reported that NK cells may
control disease flare/remission in BD patients via NK
type 2-mediated modulation of the Th1 response [29].
A possible interaction exists between the increased
Th17 and the paucity of NK cells. NK cells are able to
down-regulate Th17 cell responses to avoid pathologic
autoimmunity. In T-bet-/-mice, the paucity of NK and
Natural killer T (NKT) cells contributes to a highly polar-
ized Th17 phenotype [30]. Wu et al. [31] demonstrated
that addition of NK cells could inhibit T-bet-deficient,
autoreactive Th17 cells in the peripheral immune system.
These findings have important implications for the devel-
opment of Th17 cell-mediated autoimmune pathology
and suggest a potential role of NK cells in modulation of
Th17 cell-mediated autoimmunity. In the lungs of BD
Figure 5 Reduced expression of CD122 (interleukin-2 receptor β [IL-2Rβ]), perforin, and granzyme in bronchoalveolar lavage from
Behçet’s disease patients. [A]: Percentages of CD3+CD122+ cells in BAL. [B] Percentages of IL-2Rβ–expressing cells in natural killer cells from 10
healthy controls 10 patients with BD, and 7 patients with rheumatoid arthritis . Freshly isolated BAL cells were stained with peridinin chlorophyll
A protein–conjugated anti-CD3, fluorescein isothiocyanate–conjugated anti-CD56, and phycoerythrin-conjugated anti-CD122 monoclonal
antibodies and then analyzed by flow cytometry. Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the
boxes represent the mean. Whiskers represent the 10th and the 90th percentiles. [C]: Expression of mRNA for CD122 (IL-2Rβ), perforin, and
granzyme in BAL cells and purified NK cells from a healthy control subject and a patient with BD. Total RNA was extracted, reverse-transcribed,
and amplified by polymerase chain reaction using primers specific for CD122, perforin, granzyme, and β-actin. PCR products were separated by
electrophoresis on 1.0% agarose gels. [D]: Perforin expression in NK cells from a healthy control subject and a patient with BD, as determined by
intracellular flow cytometry. Shaded regions represent anti-perforin monoclonal antibody (mAb); open regions represent isotype-matched control
monoclonal antibody (mAb). Histograms show the CD3+CD56+ cell population. Results are representative of 3 independent experiments.
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Th17 expression. The question remains about IL-17
effect on NK cells.
Conclusions
Pulmonary manifestations are seen in approximately 25–
30% of BD patients and represent the first cause of mor-
tality. Our phenotypic and functional findings suggested
that BAL-NK cells from BD patients could have an im-
paired differentiation. Despite the increasing NK cells in
peripheral circulation, which contrasted with failing NK
cell activity in the lung, a body of research on inflamma-
tory mechanisms in pulmonary manifestations has to be
done. It is still uncertain whether the NK cell in the lung
is friend or foe.
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